查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2048071

依曲沙布市場 - 全球產業規模、佔有率、趨勢、機會、預測：銷售管道、最終用途、地區和競爭格局，2021-2031年

Etoricoxib Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel, By End Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球依曲昔布市場預計將從 2025 年的 1.2321 億美元大幅成長至 2031 年的 2.4594 億美元，複合年成長率為 12.21%。

依曲昔布是一種選擇性COX-2抑制劑和非類固醇消炎劑（NSAID），可有效緩解多種疾病的症狀，包括類風濕性關節炎、僵直性脊椎炎和痛風。該藥市場擴張的主要驅動力是全球肌肉骨骼疾病盛行率的上升和老年人口的成長，這兩方面都需要療效顯著且持久的疼痛管理方案，同時降低其胃腸道毒性，使其低於傳統的NSAID。到2024年，肌肉骨骼疾病將佔全球失能調整後存活年（DALY）的17.1%，這將確保依曲昔佈在其核准地區擁有穩定的市場需求。

市場概覽
預測期 2027-2031
市場規模：2025年 1.2321億美元
市場規模：2031年 2.4594億美元
複合年成長率：2026-2031年 12.21%
成長最快的細分市場 直接的
最大的市場 亞太地區

市場促進因素

依曲昔布的主要市場促進因素是全球慢性肌肉骨骼疾病（如骨關節炎和類風濕性關節炎）盛行率的上升，這導致對有效抗發炎療法的需求顯著增加。這些疾病通常需要長期疼痛管理，核准的市場上對依曲昔布等選擇性COX-2抑制劑的需求也隨之增加。例如，預計到2050年，全球類風濕性關節炎患者人數將從2020年的水平成長約80.2%，這將直接推動依曲昔布的消費。此外，人口老化加劇，到2024年，65歲及以上人口將佔總人口的10.3%，增加了慢性肌肉骨骼疾病的易感性。與傳統非類固醇抗發炎藥相比，依曲昔布具有降低胃腸道出血風險的優勢，這也顯著促進了市場成長。從 Alcosia 2024 年第一季7% 的銷售額成長可以看出這一點，尤其是在亞太地區，這一成長尤為明顯。

市場挑戰

阻礙全球依托考昔市場成長的最大障礙是美國食品藥物管理局(FDA) 因擔憂其心血管血栓風險而實施的嚴格監管限制。 FDA 的核准實際上阻止了依托考昔進入美國——全球最大、盈利最高的藥品市場。因此，生產商被迫將其商業活動主要限制在歐洲和亞太地區，這極大地限制了該藥物的整體收入潛力。鑑於預計到 2024 年，僅北美地區就將佔全球藥品銷售額的 54.8%，無論依托考昔在核准地區的療效或需求如何，這一監管壁壘都構成了其成長估計值的結構性限制因素。

市場趨勢

兩大顯著趨勢正在重塑依曲昔布市場。首先，複方製劑（FDC）的激增，這類組合藥物結合了肌肉鬆弛劑和鴉片類藥物。其旨在透過多方面的鎮痛作用提高療效，改善患者遵守用藥，並減輕服用多種藥物的負擔。製藥公司正在開發雙相製劑和聯合治療，將依曲昔布與曲馬多或硫代皮質類固醇聯合使用，以更好地緩解急性肌肉骨骼疾病的疼痛。例如，依曲昔布-曲馬多雙相片劑的研究表明，其療效與單藥相當，且給藥頻率較低。其次，亞太地區（尤其是印度和中國）學名藥生產和出口的激增正在改變全球供應鏈。這些地區正利用其成本效益高的生產能力，成為非類固醇消炎劑的主要供應商，為接受依曲昔布的市場提供藥物，滿足歐洲、拉丁美洲和中東的需求。 2024-25 會計年度，印度藥品出口額達到 304.7 億美元，這就證明了這一點。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球依曲考昔細分市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 銷售管道（直接、間接）
    • 依應用領域（骨關節炎、類風濕性關節炎、僵直性脊椎炎、急性痛風性關節炎等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美三葉草市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲依曲霉素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區毛滴蟲病細分市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲地區Etricoquisa的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲 Etricoquisa 的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球依曲黴素市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Merck & Co., Inc.
  • Sun Pharmaceutical Industries Limited
  • Dr. Reddy's Laboratories Limited
  • Cipla Limited
  • Lupin Limited
  • Torrent Pharmaceuticals Limited
  • Zydus Lifesciences Limited
  • Aurobindo Pharma Limited
  • Teva Pharmaceutical Industries Ltd.
  • Alkem Laboratories Limited

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 28285

The global Etoricoxib market is projected to grow substantially from USD 123.21 Million in 2025 to USD 245.94 Million by 2031, demonstrating a 12.21% CAGR. Etoricoxib, a selective COX-2 inhibitor non-steroidal anti-inflammatory drug (NSAID), provides symptomatic relief for various conditions including osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and gout. This market expansion is primarily driven by the increasing global incidence of musculoskeletal disorders and a growing geriatric population, both necessitating effective, long-term pain management solutions with a lower gastrointestinal toxicity profile than conventional NSAIDs. Musculoskeletal conditions already account for 17.1% of global years lived with disability in 2024, creating consistent demand for Etoricoxib in regions where it is authorized.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 123.21 Million
Market Size 2031USD 245.94 Million
CAGR 2026-203112.21%
Fastest Growing SegmentDirect
Largest MarketAsia Pacific

Market Driver

The primary driver for the Etoricoxib market is the rising global prevalence of chronic musculoskeletal disorders such as osteoarthritis and rheumatoid arthritis, which creates a significant demand for effective anti-inflammatory therapies. These conditions often require prolonged pain management, intensifying the need for selective COX-2 inhibitors like Etoricoxib in approved markets. For instance, global rheumatoid arthritis cases are anticipated to increase by approximately 80.2% from 2020 levels by 2050, directly boosting the consumption of Etoricoxib. Additionally, the expanding geriatric population, which constituted 10.3% of individuals aged 65 and older in 2024, contributes significantly to market growth due to their susceptibility to chronic musculoskeletal issues and the benefit of Etoricoxib's reduced risk of gastrointestinal bleeding compared to traditional NSAIDs, as evidenced by a 7% sales increase for Arcoxia in Q1 2024, particularly in the Asia Pacific region.

Market Challenge

The most significant challenge impeding the Global Etoricoxib Market's growth is the strict regulatory exclusion imposed by the US Food and Drug Administration (FDA) due to concerns about cardiovascular thrombotic risks. This lack of FDA approval effectively prevents Etoricoxib from accessing the United States, which is the world's largest and most lucrative pharmaceutical market. Consequently, manufacturers are forced to limit their commercial operations primarily to European and Asia-Pacific regions, thereby severely capping the drug's overall revenue potential. With North America alone accounting for 54.8% of estimated global pharmaceutical sales in 2024, this regulatory barrier structurally constrains Etoricoxib's growth trajectory, regardless of its efficacy or demand in authorized territories.

Market Trends

Two notable trends are reshaping the Etoricoxib market. Firstly, there is a proliferation of Fixed-Dose Combinations (FDCs) that integrate muscle relaxants and opioids, aiming to enhance therapeutic efficacy through multimodal analgesia, improve patient compliance, and reduce the burden of multiple pills. Pharmaceutical companies are developing biphasic and combination therapies, such as Etoricoxib paired with Tramadol or Thiocolchicoside, to provide superior relief for acute musculoskeletal conditions, exemplified by a study on an Etoricoxib-Tramadol biphasic tablet demonstrating equivalent efficacy with simplified dosing. Secondly, a surge in generic manufacturing and exports from Asia-Pacific hubs, particularly India and China, is transforming the global supply chain. These regions are leveraging cost-efficient production capabilities to become the primary suppliers of non-steroidal anti-inflammatory formulations for markets that accept Etoricoxib, meeting demand in Europe, Latin America, and the Middle East, as underscored by India's pharmaceutical exports reaching USD 30.47 billion in fiscal year 2024-25.

Key Market Players

  • Merck & Co., Inc.
  • Sun Pharmaceutical Industries Limited
  • Dr. Reddy's Laboratories Limited
  • Cipla Limited
  • Lupin Limited
  • Torrent Pharmaceuticals Limited
  • Zydus Lifesciences Limited
  • Aurobindo Pharma Limited
  • Teva Pharmaceutical Industries Ltd.
  • Alkem Laboratories Limited

Report Scope

In this report, the Global Etoricoxib Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Etoricoxib Market, By Sales Channel

  • Direct
  • Indirect

Etoricoxib Market, By End Use

  • Osteoarthritis
  • Rheumatoid Arthritis
  • Ankylosing Spondylitis
  • Acute Gouty Arthritis
  • Others

Etoricoxib Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Etoricoxib Market.

Available Customizations:

Global Etoricoxib Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Etoricoxib Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Sales Channel (Direct, Indirect)
    • 5.2.2. By End Use (Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, Acute Gouty Arthritis, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Etoricoxib Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Sales Channel
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Etoricoxib Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Sales Channel
        • 6.3.1.2.2. By End Use
    • 6.3.2. Canada Etoricoxib Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Sales Channel
        • 6.3.2.2.2. By End Use
    • 6.3.3. Mexico Etoricoxib Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Sales Channel
        • 6.3.3.2.2. By End Use

7. Europe Etoricoxib Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Sales Channel
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Etoricoxib Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Sales Channel
        • 7.3.1.2.2. By End Use
    • 7.3.2. France Etoricoxib Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Sales Channel
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Etoricoxib Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Sales Channel
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Etoricoxib Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Sales Channel
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Etoricoxib Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Sales Channel
        • 7.3.5.2.2. By End Use

8. Asia Pacific Etoricoxib Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Sales Channel
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Etoricoxib Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Sales Channel
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Etoricoxib Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Sales Channel
        • 8.3.2.2.2. By End Use
    • 8.3.3. Japan Etoricoxib Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Sales Channel
        • 8.3.3.2.2. By End Use
    • 8.3.4. South Korea Etoricoxib Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Sales Channel
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Etoricoxib Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Sales Channel
        • 8.3.5.2.2. By End Use

9. Middle East & Africa Etoricoxib Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Sales Channel
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Etoricoxib Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Sales Channel
        • 9.3.1.2.2. By End Use
    • 9.3.2. UAE Etoricoxib Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Sales Channel
        • 9.3.2.2.2. By End Use
    • 9.3.3. South Africa Etoricoxib Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Sales Channel
        • 9.3.3.2.2. By End Use

10. South America Etoricoxib Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Sales Channel
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Etoricoxib Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Sales Channel
        • 10.3.1.2.2. By End Use
    • 10.3.2. Colombia Etoricoxib Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Sales Channel
        • 10.3.2.2.2. By End Use
    • 10.3.3. Argentina Etoricoxib Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Sales Channel
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Etoricoxib Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Merck & Co., Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Sun Pharmaceutical Industries Limited
  • 15.3. Dr. Reddy's Laboratories Limited
  • 15.4. Cipla Limited
  • 15.5. Lupin Limited
  • 15.6. Torrent Pharmaceuticals Limited
  • 15.7. Zydus Lifesciences Limited
  • 15.8. Aurobindo Pharma Limited
  • 15.9. Teva Pharmaceutical Industries Ltd.
  • 15.10. Alkem Laboratories Limited

16. Strategic Recommendations

17. About Us & Disclaimer